Lonza Group Ltd (SGX:O6Z) Stock Price, Trades & News

Lonza Group is a contract development and manufacturing organization. It operates under four segments: small molecules, biologics, cell and gene, and capsules and health ingredients. Lonza derives its revenue primarily from long-term supply agreements with pharmaceutical customers. The company provides development and manufacturing services throughout the entire lifecycle of a product, from drug research to commercial supply. The majority of Lonza's customers are pharmaceutical and biotechnology companies, academic institutions, and government research organizations.

Financial Strength

5/10

Name	Current	Vs Industry
Cash-To-Debt	0.12
Equity-to-Asset	0.45
Debt-to-Equity	0.51
Debt-to-EBITDA	2.75
Interest Coverage	10.22
Piotroski F-Score	7/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	3.71	Distress Grey Safe
Beneish M-Score	-3.16	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

7/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	3.6
	3-Year EBITDA Growth Rate	1.4
	3-Year EPS without NRI Growth Rate	0.7
	3-Year FCF Growth Rate	35.4
	3-Year Book Growth Rate	-7.4
	Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank	18.37
	Future 3-5Y Total Revenue Growth Rate Estimate	5.94

Momentum Rank

7/10

	Name	Current	Vs Industry		Vs History

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	1.66
	Quick Ratio	1.21
	Cash Ratio	0.12
	Days Inventory	150.81
	Days Sales Outstanding	84.76
	Days Payable	41.24

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	Dividend Payout Ratio	0.31
	3-Year Dividend Growth Rate	10.1
	3-Year Average Share Buyback Ratio	2
	Shareholder Yield %	2.69

Profitability Rank

7/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	36.56
	Operating Margin %	22.91
	Net Margin %	-1.6
	EBITDA Margin %	22.06
	FCF Margin %	2.26
	OCF Margin %	20.89
	ROE %	-1.34
	ROA %	-0.6
	ROIC %	7.48
	3-Year ROIIC %	-1.06
	ROC (Joel Greenblatt) %	13.88
	ROCE %	10.05
	Years of Profitability over Past 10-Year	9
	Moat Score	7
	Tariff Resilience Score	7

GF Value Rank

10/10

	Name	Current	Vs Industry		Vs History
	Forward PE Ratio	2.77
	PE Ratio without NRI	34.68
	Shiller PE Ratio	47.17
	PEG Ratio	4.95
	PS Ratio	5.71
	PB Ratio	4.81
	Price-to-Tangible-Book	6.69
	Price-to-Free-Cash-Flow	253.12
	Price-to-Operating-Cash-Flow	27.34
	EV-to-EBIT	29.03
	EV-to-EBITDA	28.22
	EV-to-Revenue	6.23
	EV-to-FCF	276.02
	Price-to-GF-Value	0.95
	Price-to-Graham-Number	3.21
	Earnings Yield (Greenblatt) %	3.44
	FCF Yield %	0.4
	Forward Rate of Return (Yacktman) %	6.41

Financials (Next Earnings Date:2027-01-28 Est.)

Annual Quarterly TTM

SGX:O6Z's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Guru Trades

See Details

Insider Trades

See Details

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

Lonza Group Ltd Executives

Details

GF Value™: S$82.87

SGX:O6Z

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 1 Severe warning sign with O6Z. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil S$)	11,099.973
	EPS (TTM) (S$)	-2.599
	Beta	0.0564
	3-Year Sharpe Ratio	-61.75
	3-Year Sortino Ratio	-3.46
	Volatility %	10.2
	14-Day RSI	-
	14-Day ATR (S$)	-
	20-Day SMA (S$)	79.97
	12-1 Month Momentum %	-
	52-Week Range (S$)	79.97 - 79.97
	Shares Outstanding (Mil)	69.84

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	7
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

Lonza Group Ltd Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Lonza Group Ltd Stock Events

Financials Calendars

Event	Date	Price (S$)
Fourth quarter earnings conference call for 2026	2027-01-28 14:00	In 185 days
Fourth quarter earnings results for 2026	2027-01-28	In 184 days
Second quarter earnings results for 2026	2026-07-22	79.97 (+0.00%)
CHF 5.000000 Cash Dividend	2026-05-12	79.97 (+0.00%)
General meeting for 2026	2026-05-08 10:00	79.97 (+0.00%)
Annual report for 2025	2026-04-01	79.97 (+0.00%)
Guidance call for 2026	2026-03-09 08:00	79.97 (+0.00%)
Guidance call for 2026	2026-03-06 19:00	79.97 (+0.00%)
Guidance call for 2026	2026-03-03	79.97 (+0.00%)
Fourth quarter earnings conference call for 2025	2026-01-28 14:00	79.97 (+0.00%)

Show

Entries

Lonza Group Ltd Frequently Asked Questions

What is Lonza Group Ltd(SGX:O6Z)'s stock price today?

The current price of SGX:O6Z is S$79.97. The 52 week high of SGX:O6Z is S$79.97 and 52 week low is S$79.97.

When is next earnings date of Lonza Group Ltd(SGX:O6Z)?

The next earnings date of Lonza Group Ltd(SGX:O6Z) is 2027-01-28 Est..

Does Lonza Group Ltd(SGX:O6Z) pay dividends? If so, how much?

Lonza Group Ltd(SGX:O6Z) does not pay dividend.

Press Release

	Subject	Date
	Boehringer Ingelheim broadens oncology portfolio with license for Synaffix's ADC technology	2025-01-09
	Synaffix and Mitsubishi Tanabe Pharma Sign License Agreement for ADC Technology	2025-01-09
	Elevation Oncology Licenses ADC Technology from Synaffix to Drive Pipeline Expansion	2024-12-12
	Lonza's Synaffix Collaborates with BigHat Biosciences on the Development of a Machine Learning-Designed ADC	2024-11-04
	NeuroSense Announces First Quarter 2024 Business Update	2024-05-02
	ABL Bio Taps into Synaffix ADC Technology to Accelerate Development of Bispecific ADC Products	2023-09-13
	HaemaLogiX and Lonza Collaborate to Manufacture KappaMab, a Multiple Myeloma Drug Candidate	2022-01-31
	IsoPlexis and Lonza Collaborate to Enable the Next Generation of Precision Cell Therapy Manufacturing	2020-08-20
	Lonza Opens World's Largest Dedicated Cell and-Gene-Therapy Manufacturing Facility in Pearland, Greater Houston, TX (USA)	2018-04-10

10/Page

Articles on Lonza Group Ltd

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.